Peroxisome proliferator-activated receptor gamma (PPARg) is a nuclear receptor whose activation is dependent on a ligand. PPARg activation by exogenous ligands, such as thiazolidinediones (TZDs), is a strategy in the treatment of type 2 diabetes mellitus for the improvement of insulin sensitivity. In addition to a ligand, PPARg function is also regulated by posttranslational modifications, such as phosphorylation, sumoylation, and ubiquitination. Herein, we report that the PPARg protein is modified by acetylation, which induces the PPARg function in the absence of an external ligand. We observed that histone deacetylase 3 (HDAC3) interacted with PPARg to deacetylate the protein. In immunoprecipitation assays, the HDAC3 protein was associated with the PPARg protein. Inhibition of HDAC3 using RNAi-mediated knockdown or HDAC3 inhibitor increased acetylation of the PPARg protein. Furthermore, inhibition of HDAC3 enhanced the expression of PPARg target genes such as adiponectin and aP2. The expression was associated with an increase in glucose uptake and insulin signaling in adipocytes. HDAC3 inhibition enhanced lipid accumulation during differentiation of adipocytes. PPARg acetylation was also induced by pioglitazone and acetylation was required for PPARg activation. In the absence of TZDs, the acetylation from HDAC3 inhibition was sufficient to induce the transcriptional activity of PPARg. Treating diet-induced obesity mice with HDAC3 inhibitor or pioglitazone for 2 weeks significantly improved high-fat-diet-induced insulin resistance. Our results indicate that acetylation of PPARg is a ligand-independent mechanism of PPARg activation. HDAC3 inhibitor is a potential PPARg activator for the improvement of insulin sensitivity.
Introduction
with the retinoid X receptor (RXR) when it binds to the promoter DNA of target genes. The transcriptional activity of PPARg is regulated by ligands that determine PPARg interaction with coactivators and corepressors (Berger & Moller 2002) . Thiazolidinedione (TZD) is a synthetic PPARg ligand that has been widely used in clinical practice to improve insulin sensitivity in type 2 diabetes mellitus (T2DM). In the absence of ligands, PPARg binds the corepressor that is formed by histone deacetylase 3 (HDAC3) and silencing mediator for retinoid and thyroid hormone receptors (SMRT)/nuclear receptor corepressor (NCoR) . Ligand binding leads to disassociation of the corepressor complex and induces recruitment of coactivators. Although TZDs are outstanding PPARg ligands with strong therapeutic activities in the treatment of T2DM, their side effects on the heart and bladder have caused alarm with regard to clinical applications. It is an urgent priority to identify a new PPARg activator to replace TZDs in the treatment of T2DM (Ye 2011) . For this reason, we explored a new strategy of PPARg activation with a focus on HDAC3 inhibition.
Regulation of PPARg protein by direct acetylation is a new topic in the study of PPARg function. PPARg function is regulated by posttranslational modifications such as phosphorylation (Hu et al. 1996) , sumoylation (Pascual et al. 2005) , ubiquitination (Hauser et al. 2000 , Floyd & Stephens 2002 , Christianson et al. 2008 , Anbalagan et al. 2012 , and histone acetylation (Sugii & Evans 2011 , Qiang et al. 2012 . Phosphorylation of PPARg at serine 112 and 273 inhibits PPARg transcriptional activity. Sumoylation of PPARg at lysine 107 in the AF1 region and at lysine 395 in the AF2 region (lysine 77 and 365 in PPARg1 respectively) activates PPARg by blocking the interaction between the NCoR of HDAC3 and PPARg. Ubiquitination of PPARg leads to protein degradation following PPARg activation by TZDs (Hauser et al. 2000 , Floyd & Stephens 2002 , Christianson et al. 2008 , Anbalagan et al. 2012 . It is largely unknown whether PPARg protein is acetylated and, if so, how PPARg function is regulated by acetylation. In this study, we addressed this issue by analysis of PPARg protein acetylation.
HDAC3 belongs to the class I HDAC proteins, which play important roles in the regulation of histone protein acetylation in the process of chromatin remodeling and gene transcription. HDACs have three classes, class I (HDAC1, 2, 3, 8, and 11), class II (HDAC4, 5, 6, 7, 9, and 10) (Huang et al. 2000) , and class III (SIRT1-7) (Blander & Guarente 2004) . Trichostatin-A (TSA) is a pan-HDAC inhibitor for class I and class II HDACs. In our previous studies, we reported that HDAC inhibitors such as sodium butyrate and TSA promoted ligand-induced PPARg function in adipocytes in vitro (Gao et al. 2006 ) and prevented high-fatdiet-induced obesity (DIO) in mice (Gao et al. 2009 ). HDAC3, a member of the class I HDACs, has been reported by our and other laboratories to regulate PPARg function in adipocytes (Fajas et al. 2002 , Guan et al. 2005 , Miard & Fajas 2005 , Gao et al. 2006 . However, it is not known whether HDAC3 inhibition is sufficient to activate PPARg in the absence of classical ligands.
In this study, we found that PPARg protein is acetylated. The acetylation was induced by a ligand and decreased by HDAC3. HDAC3 inhibition induced PPARg acetylation and activation in the absence of exogenous ligands. The results of this study indicate that HDAC3 inhibition could be a new approach to activate PPARg in the absence of exogenous ligands.
Materials and methods
Mouse models and treatment DIO male C57BL/6J mice were purchased from the Jackson Laboratory (Bar Harbor, ME, USA) at 16-weeks-old, and had been fed a high-fat diet (HFD, 60% calories as fat, Research Diets (New Brunswick, NJ, USA) D12492) for 10 weeks. The mice were group-housed (two to four mice per cage) in the animal facility of the Pennington Biomedical Research Center with a 12 h light:12 h darkness cycle and at a temperature of 22-24 8C. The mice had free access to water and feed. The mice were treated with HDAC3 inhibitor by i.p. injection at dose of 10 mg/kg body weight per day for 2 weeks. Pioglitazone at a dose of 10 mg/kg body weight per day was used as a positive control. The pioglitazone was administered into the diet, and this group of mice received the same amount of DMSO in PBS by i.p. injection every day. All animal experiments were approved by the Institutional Animal Care and Use Committee at the Pennington Biomedical Research Center.
Cell culture and reagents
The cell lines 3T3-L1 (CL-173) and HEK293 (CRL-1573) were purchased from the American Type Culture Collection (Manassas, VA, USA) and maintained in 10 and 5% fetal bovine serum, DMEM in a 5% CO 2 incubator. The cells were starved in DMEM containing 0.25% fatty-acidfree BSA overnight before treatment with 150 nM of HDAC3 inhibitor. HDAC3 inhibitor (cat. no. EB1003) was purchased from KeraFAST (Boston, MA, USA). Pioglitazone (cat. no. E6910) was purchased from Sigma.
Adipogenesis
3T3-L1 preadipocytes were grown to confluence in a six-well or 100-mm plate. Then they were differentiated into adipocytes using a standard protocol. The 3T3-L1 cells were incubated in the adipogenic cocktail (5 mg/ml insulin, 0.5 mM isobutylmethylxanthine, and 10 mm dexamethasone) for 2 days. This was followed by incubation in an insulin-supplemented medium for an additional 4 days. The normal medium was used at day 7 to maintain the adipocytes. Adipogenesis was quantified with Oil Red O staining, as described previously (Gao et al. 2006) .
Glucose uptake
3T3-L1 preadipocytes (5!10 5 /well) were differentiated into adipocytes in a 12-well plate. After serum starvation in 0.25% BSA DMEM overnight, the cells were treated with HDAC inhibitors, and glucose uptake was measured as described elsewhere (Gao et al. 2004) .
Immunoblot
The whole-cell lysates were prepared by sonication in lysis buffer and used in western blotting analysis, as described elsewhere (Gao et al. 2002) . Antibodies to acetyl-lysine (ab21623), b-actin (ab6276), HDAC3 (ab2379), and GFP (ab290) were purchased from Abcam (Cambridge, MA, USA). Monoclonal PPARg (E-8, sc-7273x) and HA (sc-7392) antibodies were from Santa Cruz.
Immunoprecipitation and HDAC assay
Immunoprecipitation (IP) was carried out using whole-cell lysates (400 mg of total protein), 2-4 mg of antibody, and 40 ml of protein G-Sepharose beads (Amersham Biosciences), as described elsewhere (Gao et al. 2002) . The HDAC assay was conducted using a HDAC assay kit (17-320; Millipore (Billerica, MA, USA)). Briefly, PPARg was immunoprecipitated and then was used as a substrate in HDAC assay. Recombinant HDAC3 protein (cat. no. H00008841, ABNOVA (Walnut, CA, USA)) was added into the reactions as an enzyme in the assay.
HDAC3 inhibitor specificity test
HDAC3 inhibitor specificity was measured using a Fluorde-Lys HDAC3/NCOR1 fluorometric drug discovery kit (BML-AK531, Enzo Life Science (Farmingdale, NY, USA)) and a Fluor-de-Lys HDAC1 fluorometric drug discovery assay kit (BML-AK511, Enzo Life Science) as described in the manufacturer's instructions.
I.p. insulin tolerance test
Fourteen-week-old DIO mice, which had already been given a HFD (D12492) for 8 weeks, were purchased from Jackson Laboratory (stock #000664). After quarantine, the mice were divided into three groups. Each group consisted of eight mice. For 2 weeks, 10 mg/kg body weight per day of HDAC3 inhibitor was administrated by i.p. injection. The control groups were given PBS with 0.1% DMSO (solvent). Pioglitazone was applied in the diet at the dose of 10 mg/kg body weight per day. An insulin tolerance test (ITT) was conducted by i.p. injection of insulin (I9278, Sigma) at 0.75 units/kg of body weight in mice after a 4 h fast, as described elsewhere (Gao et al. 2009 ). Blood glucose was monitored in the tail vein blood using the FreeStyle blood glucose monitoring system (TheraSense, Phoenix, AZ, USA).
Transfection and luciferase assay
Transient transfection was conducted in triplicate in 12-well plates. HEK293 cells (1.5!10 5 /well) were plated for 16 h and transfected with plasmid DNA using Lipofectamine. The PPARg reporter system was constituted using 0.2 mg each of PPRE (3!)-luciferase, PPARg2, and RXRa in each well (Gao et al. 2006 ). The cells were treated with 1 mM pioglitazone or 150 nM HDAC3 inhibitor for 16 h to activate PPARg2 after transfection for 24 h. The luciferase assay was conducted using the luciferase substrate system (Promega) with a 96-well luminometer (Gao et al. 2006) . Each experiment was repeated at least three times.
Statistical analysis
All experiments were repeated independently at least three times with consistent results. For most figures, a representative bar graph shows the meanGS.E.M. of multiple independent experiments normalized to appropriate controls. Student's t-test or one-way ANOVA was used as appropriate in statistical analyses of the data. P!0.05 was considered to indicate statistical significance.
Results

PPARg is acetylated in adipocytes
PPARg function is regulated by posttranslational modifications, such as phosphorylation (Hu et al. 1996) , sumoylation (Yang & Gregoire 2006 , Geiss-Friedlander & Melchior 2007 , and ubiquitination (Hauser et al. 2000 , Floyd & Stephens 2002 , Christianson et al. 2008 , Anbalagan et al. 2012 ). However, whether PPARg can be regulated by acetylation is not well known. We examined PPARg acetylation in 3T3-L1 adipocytes before and after differentiation. Acetylation was examined using an immunoblot with the acetylation-specific antibody after PPARg isolation by IP ( Fig. 1 ). In the undifferentiated cells, the purified PPARg protein exhibited no significant signal in the acetylation assay ( Fig. 1 ). In the differentiated cells, there are two isoforms of PPARg, PPARg1 and PPARg2, with different molecular weights. Both isoforms of PPARg proteins expressed a strong signal of acetylation (Fig. 1) . The levels of acetylation were identical between PPARg1 and PPARg2. The results indicate that PPARg protein is acetylated in the adipocytes.
HDAC3 regulates PPARg acetylation
It is generally believed that PPARg is associated with the corepressor in the absence of a ligand. Disassociation of the corepressor complex is induced by the interaction of ligand PPARg, which is required for recruitment of coactivators and acetylation of histone proteins in the initiation of gene transcription. The corepressor contains HDAC3 and SMRT or NCoR. HDAC3 inhibits transcription by deacetylating histone proteins (Zamir et al. 1997 , Treuter et al. 1998 , Hu et al. 2001 , Krogsdam et al. 2002 , Gao et al. 2005 . However, it is not known whether HDAC3 regulates acetylation of PPARg protein. To address this issue, we examined HDAC3-PPARg interaction in cells through IP. In the study, GFP-tagged HDAC3 was expressed, together with HA-tagged PPARg, in a transient cotransfection of HEK293 cells. Antibodies to GFP and HA were used to isolate HDAC3 and PPARg in IP respectively. We observed that the HDAC3 product contained PPARg and that PPARg product contained HDAC3 ( Fig. 2A) . The results indicate that HDAC3 physically interacts with PPARg. To test HDAC3 in deacetylation of PPARg, we determined their enzyme and substrate relationship. In the assay, a recombinant HDAC3 protein (cat. no. H00008841, ABNOVA) was used as the deacetylase enzyme. Acetylation was induced in HA-tagged PPARg2 in HEK 293 cells with the HDAC inhibitor TSA (200 nM for 30 min). When HDAC3 was inhibited with a chemical inhibitor (HD-75) in a deacetylation assay in test tube, PPARg acetylation was preserved by the inhibitor (Fig. 2B) . The acetylation was reduced in the absence of the inhibitor (Fig. 2B) . The results indicate that as a protein deacetylase, HDAC3 directly deacetylates PPARg protein.
We tested the specificity of the HDAC3 inhibitor HD-75 ( Fig. 2C ) using a Fluor-de-Lys HDAC3/NCOR1 fluorometric drug discovery kit and a Fluor-de-Lys HDAC1 fluorometric drug discovery assay kit. A HDAC1 assay kit was used as a control for the specificity of the HDAC3 inhibitor. These kits are ideal for chemical library screening of candidate inhibitors. In the HDAC3 assay, the deacetylase activity of HDAC3 was inhibited by the HDAC3 inhibitor at IC 50 of 150 nM. At this dosage, it only slightly inhibited HDAC1 activity (Fig. 2D ). This indicates that HD-75 has specificity for HDAC3.
PPARg acetylation was examined using the inhibition of HDAC3 in 3T3-L1 adipocytes. We tested whether HD-75 causes a strong induction of PPARg acetylation at a dose of 150 nM in 3T3-L1 adipocytes. In the study, 3T3-L1 adipocytes were treated with 150 nM of HDAC3 inhibitor for 2 h. The cells were harvested and 500 mg of the wholecell lysates protein was used in IP with anti-acetyl-lysine antibody. We detected a stronger PPARg signal in the IP product in the sample treated with the HDAC3 inhibitor. PPARg acetylation was significantly enhanced by the HDAC3 inhibitor and also in the immunoblots ( Fig. 2E ). Briefly, 40 mg of protein from 500 mg/500 ml IP samples was used for the loading control indicated by the b-actin in the immonoblot (Fig. 2E, bottom panel) . The results indicate that PPARg acetylation was regulated by the HDAC3 inhibitor in cells.
PPARg activation by the ligands has been reported to induce degradation of the PPARg protein (Hauser et al. 2000 , Floyd & Stephens 2002 . It is not known whether the ligand induces PPARg acetylation. We addressed this question by examining PPARg acetylation in pioglitazonetreated 3T3-L1 adipocytes. In cells, pioglitazone enhanced PPARg acetylation (Fig. 2F) . The results indicate that pioglitazone induces PPARg acetylation. Acetylation of PPARg by the inhibition of HDAC3 did not cause PPARg degradation. This indicates that acetylation of PPARg by the inhibition of HDAC3 may be different from pioglitazone-induced acetylation of PPARg.
HDAC3 inhibitor induces PPARg acetylation at multiple lysine sites
The PPARg acetylation sites were analyzed by mass spectrometry. In the study, PPARg was expressed in a transient transfection of HEK293 cells. Antibody to PPARg was used to isolate PPARg in IP. PPARg in the IP product was purified by SDS-PAGE. These analyses were performed by the Proteomics Core facility at Applied Biomics, Inc.
(23785 Cabot Blvd., Suite 311, Hayward, CA, USA). We used their service and detected four acetylated lysine residues in PPARg (Fig. 3) . The four acetylated lysine sites (K289, K386, K462, and K466) were detected by mass spectrometry (lower panel). The data confirmed that PPARg acetylation was induced by the HDAC3 inhibitor.
Further study is needed of the function of acetylated lysine sites in PPARg.
Acetylation induces PPARg function
To test acetylation modification in the regulation of PPARg function, we determined the transcriptional activity of PPARg by quantifying the expression of the target genes. PPARg acetylation was induced in 3T3-L1 adipocytes through the inhibition of HDAC3 activity with gene knockdown. A vector-based GFP-positive RNAi to HDAC3 was delivered by adenovirus, which infected 3T3-L1 adipocytes with 90% efficiency (Fig. 4A) . The efficiency was quantified for GFP-positive cells under a fluorescence microscope. The expression of PPARg target genes was determined using an immunoblot. In the control cells that were infected with the control virus, HDAC3 protein was observed to correspond to an abundant protein band. In the cells infected by RNAi virus, HDAC3 was reduced by 90% according to the decreased signal of the HDAC3 protein band (Fig. 4B ). Knockdown of HDAC3 significantly increased expression of PPARgresponsive genes, including aP2 (fatty acid-binding protein 4 (FABP4); Fig. 4B ). The results indicate that HDAC3 inhibition promotes the transcriptional activity of PPARg in adipocytes. HDAC3 knockdown promotes adipogenesis. PPARg induces the expression of a variety of genes in the pathways for lipid biosynthesis and storage, which is required for the differentiation of preadipocytes. Adipogenesis is often used to determine PPARg function. We induced adipogenesis to test the effects of HDAC3 inhibition on the regulation of PPARg function. HDAC3 was inhibited in 3T3-L1 preadipocytes by gene knockdown using the adenovirus RNAi delivery system (Fig. 4C) . Adipogenesis was induced at 48 h after virus infection. We observed the green fluorescence in cells from days 1 to 8 during adipogenesis (data not shown). Lipid accumulation was quantified by Oil Red O staining in the differentiated cells 8 days later. HDAC3 knockdown increased the lipid content by 30% in this adipogenesis system (Fig. 4D) . The results indicate that inhibition of HDAC3 promotes lipid accumulation in adipocytes. The result further supports the hypothesis that inhibition of HDAC3 could be an approach to promote PPARg function.
HDAC3 inhibitor promotes adipogenesis
A chemical inhibitor of HDAC3 was tested for the regulation of adipogenesis in an effort to identify a new PPARg activator independent of TZDs. In the study, activation of PPARg by the HDAC3 inhibitor was tested in the adipocyte differentiation model. The 3T3-L1 adipocytes were differentiated in the standard adipogenic cocktail. The HDAC3 inhibitor was added to the culture medium at a concentration of 150 nM during adipogenesis. Pioglitazone was used as a positive control. At the end of differentiation, the degree of differentiation was determined by Oil Red O staining of intracellular lipids. The HDAC3 inhibitor enhanced lipid accumulation in the cells, as indicated by the results (Fig. 5A) . Oil Red O staining was enhanced by 50% in the inhibitor-and pioglitazone-treated groups (Fig. 5A, lower panel) . The HDAC3 inhibitor had the same effect as pioglitazone in inducing adipogenesis. The PPARg target genes including adiponectin and aP2 were enhanced by the inhibitor and pioglitazone in the western blotting analysis (Fig. 5B ).
Comparing the HDAC3 inhibitor with pioglitazone, the HDAC3 inhibitor generated a greater increase in adiponectin expression. Adiponectin is known to promote insulin sensitivity. In a reporter assay, the HDAC3 inhibitor had the same effect as pioglitazone in inducing PPARg transcriptional activity (Fig. 5C ). The results indicate that the HDAC3 inhibitor activates PPARg function in the absence of exogenous ligands and that the potency of the HDAC3 inhibitor is similar to that of pioglitazone.
Inhibition of HDAC3 enhances insulin sensitivity
To further investigate the effect of HDAC3 inhibitor in the activation of PPARg, first, we used glucose uptake to determine PPARg function, which may enhance glucose uptake by induction of IRS2 and Glut4 in the insulinsignaling pathway. Pioglitazone was used as a positive control. The results indicated that PPARg ligand increased insulin-induced glucose uptake in 3T3-L1 adipocytes (Fig. 6A) . The HDAC3 inhibitor exhibited the same activity in the promotion of glucose uptake (Fig. 6A ). Insulin signaling activity was examined by AKT serine 473 phosphorylation. Insulin-induced phosphorylation of AKT serine 473 was enhanced by the HDAC3 inhibitor (Fig. 6B) . To test whether HDAC3 inhibitor enhances insulin sensitivity in vivo, we treated DIO mice with HDAC3 inhibitor at 10 a dose of mg/kg body weight per day for 2 weeks. The treatment was given to 16-week-old DIO mice, which had been fed a HFD for 10 weeks. In our previous studies, feeding B6 mice for 12 weeks with a HFD induced insulin resistance. Pioglitazone at the dose of 10 mg/kg body weight per day was used as a positive control. The pioglitazone was administered into the diet, and this group of mice received the same amount of DMSO in PBS by i.p. injection every day. After 2 weeks of treatment, insulin sensitivity was evaluated by an ITT after 4 h of fasting. The HDAC3 inhibitor and pioglitazone both significantly reduced glucose levels and enhanced insulin sensitivity ( Fig. 6C and D) . Body weight and food intake were not changed in the mice by the 2-week treatment. The results indicate that the HDAC3 inhibitor enhanced PPARg function, serving as an insulin sensitizer in adipocytes.
Discussion
Our results indicate that acetylation of PPARg is induced by pioglitazone. Pioglitazone induces PPARg activation through recruitment of coactivators and disassociation of corepressors. The coactivators contribute to the transcriptional activation by inducing histone acetylation, which is required for chromatin structure change. There has been little information available about PPARg acetylation, though PPARg activity is regulated by protein modification such as phosphorylation (Hu et al. 1996) , sumoylation (Pascual et al. 2005) , and ubiquitination (Hauser et al. 2000 , Floyd & Stephens 2002 , Christianson et al. 2008 , Anbalagan et al. 2012 . In a recent study, it was reported that PPARg acetylation (lysine 268 and 293) was induced by a ligand and decreased by SIRT1 in HEK293 cells (Qiang et al. 2012) . Although the results of that study indicated a role of acetylation in the regulation of PPARg function, it was not known whether the acetylation happens in the absence of a ligand. In that study, PPARg acetylation was regulated by SIRT1 and the effect was investigated in 'browning' of white adipose tissue. The acetylation inhibits brown adipocyte differentiation in the white adipose tissue (inguinal fat) by blocking the interaction of PPARg with the coactivator PRDM16. It was reported that inhibition of the acetylation promoted preadipocyte differentiation into brown adipocytes in response to cold challenge at 4 8C in a cold room. The results indicated that PPARg acetylation favors lipid accumulation and preadipocyte differentiation into white adipocytes, which disfavors brown adipocyte differentiation. HDAC1/ HDAC3 was reported to modulate PPARg transcription through the sumoylated CEBPD in hepatic lipogenesis (Lai et al. 2008) . However, there is no report that PPARg was acetylated by HDAC1/HDAC3. Our results indicate that HDAC3 regulates PPARg acetylation and function directly.
In this current study, we observed that PPARg acetylation was induced by pioglitazone ( Fig. 2F ). PPARg acetylation was induced by the inhibition of HDAC3 in the absence of an exogenous ligand. The ligand-independent acetylation enhanced the transcriptional activity of PPARg, as indicated by PPARg target gene expression, lipid accumulation in adipogenesis, and insulin-induced indicate uptake. Our results indicate that PPARg acetylation could be a new approach to increase PPARg activity and that this acetylation may occur in the absence of exogenous ligands. It is not known whether acetylation correlates with phosphorylation, sumoylation, and ubiquitination of the PPARg protein.
In terms of the mechanism by which PPARg acetylation leads to PPARg activation, we would like to propose a model here. In this model, we suggest that there is a basal level of acetylation of the PPARg protein in the absence of a ligand. The corepressor removes the acetylation constantly to prevent PPARg activation without a ligand. Inhibition of HDAC3 increased glucose uptake and insulin sensitivity. (A) Glucose uptake. Fully differentiated 3T3-L1 adipocytes were treated with H3I overnight, and then glucose uptake was measured. *Drug vs control;
The corepressor activity is abolished when it is disassociated from the PPARg protein in response to a ligand. When the corepressor activity is inhibited, the acetylation accumulates in the PPARg protein in the absence of deacetylation activity. Acetylated PPARg induces the recruitment of acetyltransferases (HATs), such as p300/CBP, to induce gene transcription, which in turn induces histone acetylation in PPARg-responsive genes (Graves et al. 1992 , Freedman 1999 . This model explains the role of PPARg acetylation in PPARg activation in the absence of a ligand. Our results indicate that PPARg acetylation is coupled with histone acetylation. Histone acetylation is required for gene transcription, but histone acetylation is probably a consequence of PPARg acetylation. This possibility remains to be tested.
Our resuls indicate that the HDAC3 inhibitor is a new PPARg activator that exhibits potency similar to that of pioglitazone. The TZDs are the most powerful insulin sensitizer in the treatment of T2DM (Tontonoz & Spiegelman 2008) . TZD-based medicines include pioglitazone (Actos by Takeda Pharmaceuticals (Chuo-ku, Osaka, Japan)) and rosiglitazone (Avandia by GlaxoSmithKline). Although TZD-based medicines have outstanding therapeutic activities, the adverse effects, such as heart attacks and bladder cancer, have significantly reduced their applications in the treatment of T2DM (Rosen 2010 , Ferrara et al. 2011 , Cariou et al. 2012 , Tseng 2012 . We believe that PPARg activation remains an excellent approach in the treatment of T2DM. All of the TZDbased medicines activate PPARg. However, their side effects are different for the heart and bladder, indicating that the side effects are not due to PPARg activation. It is likely that the side effects are the off-target activities of the medicine. Our results indicate that the HDAC3 inhibitor is a potential new generation of PPARg activator and an insulin sensitizer. Inhibition of HDAC3 is beneficial in preventing neuronal death (Bardai et al. 2012) , improving b-cell function (Chou et al. 2012) , and having anticancer effects (Escaffit et al. 2007 , Bhaskara et al. 2008 . Moreover, inhibition of HDAC3 promotes the transcriptional activities of myocyte enhancer factor 2 (Naya & Olson 1999 , Gregoire et al. 2007 , implying that inhibition of HDAC3 may protect heart function. In our previous study, paninhibitors of HDACs prevented HFD-induced obesity and insulin resistance in mice (Gao et al. 2009 ). These findings indicate that HDAC3 inhibitor may be able to avoid the side effects of synthetic PPARg ligands in vivo.
In conclusion, we report that the transcription factor PPARg is modulated by acetylation in response to ligands.
The acetylation is sufficient to induce PPARg function in the absence of exogenous ligands. A HDAC3 inhibitor is able to activate PPARg in a ligand-independent manner. These results indicate that the HDAC3 inhibitor may be a ligand-independent PPARg activator. Inhibition of HDAC3 may represent a new approach for improving insulin sensitivity in the treatment of T2DM.
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